We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
-22.41%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$1.2B
AUM Growth
-$529M
(-31%)
Cap. Flow
-$190M
Cap. Flow
% of AUM
-15.87%
Top 10 Holdings %
Top 10 Hldgs %
48.83%
Holding
40
New
6
Increased
10
Reduced
9
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ironwood Pharmaceuticals
IRWD
|
+$48.8M |
| 2 |
GDS Holdings
GDS
|
+$36.2M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$23.6M |
| 4 |
VeriSign
VRSN
|
+$23.6M |
| 5 |
Shake Shack
SHAK
|
+$23.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HCA Healthcare
HCA
|
+$110M |
| 2 |
Zimmer Biomet
ZBH
|
+$92.7M |
| 3 |
DexCom
DXCM
|
+$43.5M |
| 4 |
MSGN
MSG Networks Inc.
MSGN
|
+$34.7M |
| 5 |
ATVI
Activision Blizzard
ATVI
|
+$29.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.45% |
| 2 | Technology | 15.13% |
| 3 | Consumer Discretionary | 13.34% |
| 4 | Communication Services | 6.41% |
| 5 | Consumer Staples | 5.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Atara Biotherapeutics
ATRA
$74.4M
| $76.7M | 6.39% |
88,277
-10,093
| -10% | -$9.37M |
|
2
GoDaddy
GDDY
$10.5B
| $72.6M | 6.06% |
1,106,900
| – | – |
|
3
Heron Therapeutics
HRTX
$95.1M
| $64.4M | 5.37% |
2,482,309
+192,245
| +8% | +$5.29M |
|
4
Post Holdings
POST
$4.15B
| $63.3M | 5.27% |
1,084,568
-330,027
| -23% | -$19.9M |
|
|
MDCO
5
DELISTED
Medicines Co
MDCO
| $58.6M | 4.88% |
3,060,671
+720,981
| +31% | +$16.8M |
|
6
Morgan Stanley
MS
$332B
| $54.1M | 4.51% |
1,363,307
+220,198
| +19% | +$9.61M |
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $51M | 4.25% |
4,773,718
-756,310
| -14% | -$9.95M |
|
8
Charter Communications
CHTR
$17.4B
| $48.9M | 4.07% |
171,451
-16,713
| -9% | -$5.24M |
|
9
MGM Resorts International
MGM
$11.4B
| $48.2M | 4.02% |
1,986,689
+33,917
| +2% | +$885K |
|
10
Alnylam Pharmaceuticals
ALNY
$27.1B
| $48M | 4% |
658,785
-64,225
| -9% | -$4.94M |
|
|
FDC
11
DELISTED
First Data Corporation
FDC
| $45M | 3.75% |
2,658,994
| – | – |
|
|
12
Ironwood Pharmaceuticals
IRWD
$690M
| $43.3M | 3.61% |
4,993,179
+4,250,641
| +572% | +$48.8M |
|
|
13
VeriSign
VRSN
$26.1B
| $43.1M | 3.6% |
290,843
+157,387
| +118% | +$23.6M |
|
14
Caesars Entertainment
CZR
$6.06B
| $40.3M | 3.36% |
1,112,836
| – | – |
|
|
WMGI
15
DELISTED
Wright Medical Group Inc
WMGI
| $38.8M | 3.23% |
1,424,239
-799,018
| -36% | -$22.1M |
|
16
Nektar Therapeutics
NKTR
$2.38B
| $37.3M | 3.11% |
75,628
| – | – |
|
17
Viasat
VSAT
$10.6B
| $33.7M | 2.81% |
570,979
| – | – |
|
|
18
GDS Holdings
GDS
$6.49B
| $32.1M | 2.67% |
+1,389,514
| New | +$36.2M |
|
|
CZR
19
DELISTED
Caesars Entertainment Corporation
CZR
| $30.2M | 2.52% |
4,452,889
+1,522,348
| +52% | +$12.8M |
|
20
Liberty Broadband Class A
LBRDA
$4.9B
| $28M | 2.34% |
390,292
| – | – |
|
21
Rocket Pharmaceuticals
RCKT
$337M
| $26M | 2.17% |
1,752,902
| – | – |
|
22
Teva Pharmaceuticals
TEVA
$40.9B
| $23.1M | 1.93% |
1,500,000
| – | – |
|
|
23
Shake Shack
SHAK
$2.54B
| $20.8M | 1.73% |
+456,923
| New | +$23.6M |
|
|
GDEN
24
DELISTED
Golden Entertainment
GDEN
| $20.6M | 1.71% |
1,282,755
+381,312
| +42% | +$6.94M |
|
|
ALXN
25
DELISTED
Alexion Pharmaceuticals
ALXN
| $19.5M | 1.62% |
+200,049
| New | +$23.6M |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q4 2018 Portfolio in Review
As of Q4 2018, Bridger Management held 40 positions worth $1.2B, down 31% from $1.73B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Bridger Management withdrew a net $190M in Q4 2018, closing 6 positions and reducing 9 holdings. Its most notable exit was HCA Healthcare, an estimated $110M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 47% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Bridger Management opened a new position in GDS Holdings worth $32.1M.
- Bridger Management's largest Q4 2018 buy was GDS Holdings: 1,389,514 shares worth $32.1M.
- Bridger Management added most to Ironwood Pharmaceuticals in Q4 2018, an estimated $48.8M increase.
- Bridger Management's biggest Q4 2018 reduction was DexCom, cutting an estimated $43.5M.
- Bridger Management fully exited HCA Healthcare in Q4 2018, selling an estimated $110M.
- Bridger Management's ten largest holdings make up 49% of its $1.2B portfolio in Q4 2018.
- Bridger Management opened 6 new positions and closed 6 in Q4 2018.
- Bridger Management's portfolio value fell 31% quarter-over-quarter to $1.2B.
Based on Bridger Management's 13F filing for Q4 2018, filed 14 Feb 2019.